This site is intended for Canadian healthcare professionals only.

EN ENGLISH / FR French

For consumers

EN ENGLISH / FR French

About CoolSculpting^®

CoolSculpting^® Science
CoolSculpting^® System

CoolSculpting^® for your practice

Patient Demand
Results
Clinic Resources & Support

FAQs

For consumers
Contact Us

Site map

Homepage
About CoolSculpting^®
What is CoolSculpting^®?
Capital Equipment
CoolSculpting^® for Your Practice
Demand
Results & Testimonials
Resources & Support
FAQs
Contact Us
Indications & Important Safety Information
Site map

Privacy Policy
Terms of Use
Site Map
Contact Us
Indications & Important Safety Information
Cookies Settings

CoolSculpting Indications

The CoolSculpting® System, also labeled as the ZELTIQ^® System or the ZELTIQ^® Breeze System (system), is a non-invasive thermoelectric cooling and heating device that applies controlled cooling or heating to a treatment site on the patient’s skin. Uses of the system in cooling mode include: fat layer reduction through cold-assisted lipolysis, minimizing pain and thermal injury during laser and dermatological treatments, and acting as a local anesthetic for procedures that induce minor local discomfort. The system can also provide localized thermal therapy (hot or cold) to minimize pain for post-traumatic and/or post-surgical pain and to temporarily relieve minor aches and pains and muscle spasms. The optional massage function can also be used for: temporary relief of minor muscle aches, pain, and spasm, and temporary improvement in local circulation.

The use of the CoolSculpting® system has not been studied in children, or those who are pregnant or lactating.¹

The CoolSculpting^® procedure is not for you if you have the following:¹

Cryoglobulinaemia
Cold agglutinin disease
Paroxysmal cold haemoglobinuria
Areas of impaired peripheral circulation
Pregnancy and lactation

Use caution before performing localized cooling under the following conditions, the effects of which have not been studied:¹

Known sensitivity to cold such as cold urticaria, Raynaud’s disease, or chilblains (pernio)
Known sensitivity or allergy to fructose, glycerin, isopropyl alcohol, or propylene glycol
Impaired peripheral circulation in the area to be treated
Neuropathic disorders such as post-herpetic neuralgia or diabetic neuropathy
Impaired skin sensation
Open or infected wounds
Bleeding disorders or concomitant use of blood thinners
Recent surgery or scar tissue in the area to be treated
Hernia in or adjacent to the treatment site
Skin conditions such as eczema, dermatitis or rashes in the area to be treated
The effect of performing treatments directly overactive implanted devices, such as pacemakers and defibrillators, is not known
Areas of recent bleeding or hemorrhage (heating)

The following effects can occur in the treatment area during and after a treatment.¹

These effects are temporary and generally resolve within days or weeks.¹

During a treatment:¹

Sensations of pulling, tugging and mild pinching at the treatment site
Intense cold, tingling, stinging, aching, and cramping. These sensations may subside as the area becomes numb

Immediately after a treatment:¹

Redness and firmness
Transient blanching and/or mild bruising around the edges of the treatment area
Tingling and stinging

1 to 2 weeks after a treatment:¹

Redness, bruising, and swelling
Tenderness, cramping, and aching
Itching, skin sensitivity, tingling and numbness. Numbness can persist up to several weeks after a treatment
Sensation of fullness in the back of the throat after submental area treatment

Rare side effects:¹

Paradoxical hyperplasia: visibly enlarged tissue volume within the treatment area, which may develop 2 to 5 months after treatment. Surgical intervention may be required
Late-onset pain with a typical onset several days after a treatment and resolution within several weeks
Freeze burn:* first- and second-degree freeze burn may occur during treatment. It typically resolves without sequelae with proper care
Vasovagal symptoms:* dizziness, lightheadedness, nausea, flushing, sweating, or fainting during or immediately after the treatment
Subcutaneous induration: generalized hardness and/or discrete nodules within the treatment area, which may develop after the treatment, and may present with pain and/or discomfort
Hyperpigmentation:* hyperpigmentation may occur after treatment. Typically, it resolves spontaneously
Hernia: treatment may cause new hernia formation or exacerbate pre-existing hernia, which may require surgical repair

* Freeze burn, vasovagal symptoms, and hyperpigmentation were observed during clinical trials, while the others were reported in post-market use.

1. Allergan Inc. CoolSculpting® system user manual. BRZ-101-TUM-EN3-J. 2018

BRILLIANT DISTINCTIONS^® Loyalty Program is owned by Allergan Inc.
BRILLIANT DISTINCTIONS^® and its design are trademarks of Allergan Inc.
The CoolSculpting^® logo and the Snowflake design are registered trademarks of Allergan Aesthetics, an AbbVie company.
CoolSculpting^® systems, applicators and
cards are medical devices Class I or Class IIa CE0197. ZELTIQ is part of Allergan Aesthetics, an AbbVie company. All rights reserved.

www.allerganaesthetics.ca
© 2024 Allergan Inc. All rights reserved. CA-ABBV-230099